Table 4. Cumulative difference in vaccinations from the baseline period (January 2016–February 2020) in countries, 2020–2021.
| Country and vaccine (dose) | March–August 2020 |
September 2020–February 2021 |
March–August 2021 |
March 2020–August 2021 |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cumulative observed counts, true value | Cumulative difference, estimated counts (95% PI) | Difference over expected, estimated % (95% PI) | Cumulative observed counts, true value | Cumulative difference, estimated counts (95% PI) | Difference over expected, estimated % (95% PI) | Cumulative observed counts, true value | Cumulative difference, estimated counts (95% PI) | Difference over expected, estimated % (95% PI) | Cumulative observed counts, true value | Cumulative difference, estimated counts (95% PI) | Difference over expected, estimated % (95% PI) | ||||
| Haiti | |||||||||||||||
| Bacillus Calmette–Guerin (1) | 4904 | -1083.5 (-2782.2 to 165) | -18.1% (-36.2 to 3.5) | 4020 | -2414 (-4419 to -901.6) | -37.5% (-52.4 to -18.3) | 7142 | 939 (-1235.8 to 2452.1) | 15.1% (-14.7 to 52.3) | 16066 | -2666 (-7471.5 to 963.1) | -14.2% (-31.7 to 6.4) | |||
| Oral or inactivated polio (0) | 1608 | -337.5 (-1996.1 to 524.8) | -17.3% (-55.4 to 48.4) | 2103 | -159.5 (-2160.1 to 898.8) | -7% (-50.7 to 74.6) | 1567 | -429 (-2923.7 to 516.1) | -21.5% (-65.1 to 49.1) | 5278 | -953.5 (-5926.8 to 1482) | -15.3% (-52.9 to 39) | |||
| Oral or inactivated polio (1) | 7615 | -2301.5 (-6452.3 to 746.6) | -23.2% (-45.9 to 10.9) | 11390 | 587.5 (-4841.4 to 3799.5) | 5.4% (-29.8 to 50.1) | 10691 | -32.5 (-6786.4 to 3704.1) | -0.3% (-38.8 to 53) | 29696 | -2425 (-14999 to 6431.5) | -7.5% (-33.6 to 27.6) | |||
| Oral or inactivated polio (2) | 3315 | -1825.5 (-6535.2 to 879.1) | -35.5% (-66.3 to 36.1) | 5057 | -166.5 (-5813.9 to 2609.6) | -3.2% (-53.5 to 106.6) | 5054 | -801.5 (-9684.3 to 2483.3) | -13.7% (-65.7 to 96.6) | 13426 | -2714 (-18131.2 to 4662.7) | -16.8% (-57.5 to 53.2) | |||
| Oral or inactivated polio (3) | 2313 | -982 (-4051.5 to 688.3) | -29.8% (-63.7 to 42.4) | 3499 | 211 (-3509.4 to 1881.6) | 6.4% (-50.1 to 116.3) | 3650 | -74 (-4643.6 to 1967.5) | -2% (-56 to 116.9) | 9462 | -1186 (-9607.1 to 3615.6) | -11.1% (-50.4 to 61.8) | |||
| Pentavalent (1) | 4934 | -952 (-3036.5 to 697.5) | -16.2% (-38.1 to 16.5) | 7212 | 898 (-2021 to 2650.2) | 14.2% (-21.9 to 58.1) | 6365 | -30.5 (-3180.3 to 2004.8) | -0.5% (-33.3 to 46) | 18511 | -248.5 (-6455.2 to 4600.5) | -1.3% (-25.9 to 33.1) | |||
| Pentavalent (2) | 4384 | -856 (-2568.1 to 484.2) | -16.3% (-36.9 to 12.4) | 5482 | 820 (-1132.2 to 2083.3) | 17.6% (-17.1 to 61.3) | 5947 | 442.5 (-1988.5 to 2073.7) | 8% (-25.1 to 53.5) | 15813 | 252.5 (-4170.2 to 3995.4) | 1.6% (-20.9 to 33.8) | |||
| Pentavalent (3) | 3722 | -993.5 (-2485.8 to 107.3) | -21.1% (-40 to 3) | 4375 | 596.5 (-652.8 to 1524.4) | 15.8% (-13 to 53.5) | 5522 | 647.5 (-1378.7 to 1959) | 13.3% (-20 to 55) | 13619 | 130.5 (-3519.5 to 3002.8) | 1% (-20.5 to 28.3) | |||
| Pneumococcal conjugate (1) | 5313 | 371 (-4401.6 to 2858.1) | 7.5% (-45.3 to 116.4) | 4801 | -195.5 (-4019 to 1965.7) | -3.9% (-45.6 to 69.3) | 6773 | 1924.5 (-2280.7 to 4320) | 39.7% (-25.2 to 176.2) | 16887 | 1694.5 (-6162 to 6835.5) | 11.2% (-26.7 to 68) | |||
| Pneumococcal conjugate (2) | 4385 | 677.5 (-1952.2 to 2148.1) | 18.3% (-30.8 to 96) | 3690 | 77 (-2424.3 to 1555) | 2.1% (-39.6 to 72.8) | 5213 | 1469.5 (-1111 to 2896.3) | 39.3% (-17.6 to 125) | 13288 | 1986.5 (-2885.4 to 5166.3) | 17.6% (-17.8 to 63.6) | |||
| Pneumococcal conjugate (3) | 3496 | 533 (-2077.2 to 1997.2) | 18% (-37.3 to 133.3) | 2900 | 200.5 (-2265.3 to 1371.9) | 7.4% (-43.9 to 89.8) | 4148 | 1251 (-1388.3 to 2688.1) | 43.2% (-25.1 to 184.1) | 10544 | 1749.5 (-2726.8 to 4706.6) | 19.9% (-20.5 to 80.6) | |||
| Rotavirus (1) | 4621 | -737 (-3478.8 to 1232.1) | -13.8% (-42.9 to 36.4) | 6297 | 733 (-2560 to 2645.6) | 13.2% (-28.9 to 72.5) | 4859 | -863.5 (-5157.4 to 1434.3) | -15.1% (-51.5 to 41.9) | 15777 | -1003 (-9018.9 to 4151.9) | -6% (-36.4 to 35.7) | |||
| Rotavirus (2) | 3775 | -798.5 (-3486.7 to 977.5) | -17.5% (-48 to 34.9) | 4607 | 640.5 (-1637.6 to 2085.5) | 16.1% (-26.2 to 82.7) | 4114 | -635.5 (-4372.7 to 1401.6) | -13.4% (-51.5 to 51.7) | 12496 | -1114 (-7852.5 to 3672.1) | -8.2% (-38.6 to 41.6) | |||
| Measles (1) | 2700 | -1004.5 (-1855.1 to -377.4) | -27.1% (-40.7 to -12.3) | 4181 | 428 (-426.6 to 1130.3) | 11.4% (-9.3 to 37.1) | 4022 | 175 (-918.6 to 961.1) | 4.5% (-18.6 to 31.4) | 10903 | -478 (-2704 to 1286.5) | -4.2% (-19.9 to 13.4) | |||
| Lesotho | |||||||||||||||
| Bacillus Calmette–Guerin (1) | 417 | -51 (-211.6 to 70) | -10.9% (-33.7 to 20.2) | 429 | -80 (-250 to 48.5) | -15.7% (-36.8 to 12.8) | 426 | -50 (-271.6 to 88) | -10.5% (-38.9 to 26) | 1272 | -195 (-598.2 to 154.5) | -13.3% (-32 to 13.8) | |||
| Oral or inactivated polio (0) | 339 | -67.5 (-146.5 to -1) | -16.6% (-30.2 to -0.3) | 384 | -71.5 (-162 to 4.6) | -15.7% (-29.7 to 1.2) | 360 | -73 (-171.1 to 4.5) | -16.9% (-32.2 to 1.3) | 1083 | -211.5 (-427.5 to -40.5) | -16.3% (-28.3 to -3.6) | |||
| Oral or inactivated polio (1) | 457 | -16 (-93.5 to 59) | -3.4% (-17 to 14.8) | 604 | 89.5 (-5.5 to 175) | 17.4% (-0.9 to 40.8) | 520 | 72 (-13.5 to 155) | 16.1% (-2.5 to 42.5) | 1581 | 145.5 (-43 to 330) | 10.1% (-2.7 to 26.4) | |||
| Oral or inactivated polio (2) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
| Oral or inactivated polio (3) | 475 | -26 (-107.5 to 51) | -5.2% (-18.5 to 12) | 505 | 7 (-79.5 to 81) | 1.4% (-13.6 to 19.1) | 554 | 66 (-30.1 to 138) | 13.5% (-5.2 to 33.2) | 1534 | 45 (-170.7 to 212.6) | 3% (-10 to 16.1) | |||
| Pentavalent (1) | 461 | -26 (-115.5 to 48) | -5.3% (-20 to 11.6) | 604 | 79 (-25 to 168) | 15% (-4 to 38.5) | 520 | 58 (-39.6 to 147) | 12.6% (-7.1 to 39.4) | 1585 | 106.5 (-109 to 310.6) | 7.2% (-6.4 to 24.4) | |||
| Pentavalent (2) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
| Pentavalent (3) | 422 | -55 (-130.5 to 19.5) | -11.5% (-23.6 to 4.9) | 430 | -56 (-137.5 to 22) | -11.5% (-24.2 to 5.4) | 495 | 26.5 (-71.5 to 104.6) | 5.7% (-12.6 to 26.8) | 1347 | -84 (-280.5 to 91.1) | -5.9% (-17.2 to 7.3) | |||
| Pneumococcal conjugate (1) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
| Pneumococcal conjugate (2) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
| Pneumococcal conjugate (3) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
| Rotavirus (1) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
| Rotavirus (2) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
| Measles (1) | 453 | -34 (-161.1 to 64) | -7% (-26.2 to 16.5) | 361 | -50 (-184.5 to 55.5) | -12.2% (-33.8 to 18.2) | 416 | -78 (-250 to 52) | -15.8% (-37.5 to 14.3) | 1230 | -164 (-495 to 100.5) | -11.8% (-28.7 to 8.9) | |||
| Liberia | |||||||||||||||
| Bacillus Calmette–Guerin (1) | 1123 | -97 (-365 to 108.5) | -8% (-24.5 to 10.7) | 1129 | 247.5 (70.5 to 407.5) | 28.1% (6.7 to 56.5) | 1407 | 242 (-73 to 463.5) | 20.8% (-4.9 to 49.1) | 3659 | 398 (-211.3 to 869.9) | 12.2% (-5.5 to 31.2) | |||
| Oral or inactivated polio (0) | 927 | -89 (-276.5 to 63.5) | -8.8% (-23 to 7.4) | 832 | 102.5 (-37 to 218.6) | 14.1% (-4.3 to 35.6) | 785 | -206 (-418.6 to -32) | -20.8% (-34.8 to -3.9) | 2544 | -197.5 (-673.5 to 161.1) | -7.2% (-20.9 to 6.8) | |||
| Oral or inactivated polio (1) | 1198 | -171 (-400.6 to 45.5) | -12.5% (-25.1 to 4) | 1774 | 630.5 (438.5 to 806) | 55.1% (32.8 to 83.3) | 1292 | -50.5 (-354.7 to 179.2) | -3.8% (-21.5 to 16.1) | 4264 | 399 (-138 to 897.5) | 10.3% (-3.1 to 26.7) | |||
| Oral or inactivated polio (2) | 1062 | -212 (-568.1 to 3) | -16.6% (-34.9 to 0.3) | 1707 | 616.5 (355.5 to 837.5) | 56.5% (26.3 to 96.3) | 1232 | -53 (-412.1 to 211.6) | -4.1% (-25.1 to 20.7) | 4001 | 328 (-327.8 to 874) | 8.9% (-7.6 to 28) | |||
| Oral or inactivated polio (3) | 1041 | -292 (-571.1 to -89.4) | -21.9% (-35.4 to -7.9) | 1717 | 517.5 (272.4 to 720.1) | 43.1% (18.9 to 72.2) | 1167 | -184 (-533.3 to 47.1) | -13.6% (-31.4 to 4.2) | 3925 | 23.5 (-585.7 to 525.2) | 0.6% (-13 to 15.4) | |||
| Pentavalent (1) | 1190 | -169.5 (-406.6 to 11.6) | -12.5% (-25.5 to 1) | 1423 | 274 (84.9 to 450.1) | 23.8% (6.3 to 46.3) | 1768 | 429 (161.8 to 666.1) | 32% (10.1 to 60.5) | 4381 | 529 (11.7 to 979.1) | 13.7% (0.3 to 28.8) | |||
| Pentavalent (2) | 1063 | -223.5 (-487.8 to -27) | -17.4% (-31.5 to -2.5) | 1398 | 301 (88.4 to 488) | 27.4% (6.8 to 53.6) | 1655 | 372.5 (62.9 to 594.6) | 29% (4 to 56.1) | 4116 | 436.5 (-145.8 to 882.9) | 11.9% (-3.4 to 27.3) | |||
| Pentavalent (3) | 1035 | -312.5 (-594.5 to -105) | -23.2% (-36.5 to -9.2) | 1492 | 276 (8 to 459) | 22.7% (0.5 to 44.4) | 1573 | 195 (-91.1 to 430.5) | 14.2% (-5.5 to 37.7) | 4100 | 139.5 (-479.5 to 664.5) | 3.5% (-10.5 to 19.3) | |||
| Pneumococcal conjugate (1) | 1196 | -174 (-405.5 to 0) | -12.7% (-25.3 to 0) | 1533 | 384 (197.4 to 558.1) | 33.4% (14.8 to 57.3) | 1769 | 417 (129.4 to 642.5) | 30.8% (7.9 to 57) | 4498 | 618.5 (96 to 1067) | 15.9% (2.2 to 31.1) | |||
| Pneumococcal conjugate (2) | 1141 | -162 (-424.6 to 43) | -12.4% (-27.1 to 3.9) | 1530 | 418 (192 to 606) | 37.6% (14.3 to 65.6) | 1653 | 338 (50.4 to 597.3) | 25.7% (3.1 to 56.6) | 4324 | 584 (-14.6 to 1146.6) | 15.6% (-0.3 to 36.1) | |||
| Pneumococcal conjugate (3) | 1041 | -298.5 (-589 to -103) | -22.3% (-36.1 to -9) | 1541 | 328 (78.8 to 549) | 27% (5.4 to 55.3) | 1611 | 251.5 (-49.5 to 468.5) | 18.5% (-3 to 41) | 4193 | 279.5 (-362.8 to 793.1) | 7.1% (-8 to 23.3) | |||
| Rotavirus (1) | 1116 | -619 (-908 to -419.3) | -35.7% (-44.9 to -27.3) | 1607 | 79 (-233.2 to 246.6) | 5.2% (-12.7 to 18.1) | 1772 | -215.5 (-713.6 to 23.5) | -10.8% (-28.7 to 1.3) | 4495 | -761.5 (-1602.4 to -282.2) | -14.5% (-26.3 to -5.9) | |||
| Rotavirus (2) | 961 | -618 (-859.2 to -457) | -39.1% (-47.2 to -32.2) | 1280 | -183.5 (-476 to -33) | -12.5% (-27.1 to -2.5) | 1653 | -223.5 (-632.7 to -34.1) | -11.9% (-27.7 to -2) | 3894 | -1041.5 (-1667.5 to -656.9) | -21.1% (-30 to -14.4) | |||
| Measles (1) | 915 | -422 (-729.5 to -158.9) | -31.6% (-44.4 to -14.8) | 1552 | 373 (78.4 to 617.5) | 31.6% (5.3 to 66.1) | 1488 | 70 (-344.2 to 394.6) | 4.9% (-18.8 to 36.1) | 3955 | 15 (-810 to 716.5) | 0.4% (-17 to 22.1) | |||
| Malawi | |||||||||||||||
| Bacillus Calmette–Guerin (1) | 3110 | 101 (-322.7 to 392.5) | 3.4% (-9.4 to 14.4) | 3046 | -470.5 (-887.2 to -181) | -13.4% (-22.6 to -5.6) | 2751 | -596 (-1146.8 to -218.2) | -17.8% (-29.4 to -7.3) | 8907 | -977.5 (-2051.9 to -219) | -9.9% (-18.7 to -2.4) | |||
| Oral or inactivated polio (0) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
| Oral or inactivated polio (1) | 5969 | 139 (-373 to 529.4) | 2.4% (-5.9 to 9.7) | 5893 | -1296.5 (-1936.7 to -855.9) | -18% (-24.7 to -12.7) | 6157 | -1749 (-2537.1 to -1180.5) | -22.1% (-29.2 to -16.1) | 18019 | -2958.5 (-4320.1 to -1823) | -14.1% (-19.3 to -9.2) | |||
| Oral or inactivated polio (2) | 2898 | 396.5 (214 to 568.5) | 15.9% (8 to 24.4) | 2799 | -133.5 (-364.7 to 63.5) | -4.6% (-11.5 to 2.3) | 2674 | -74 (-304.2 to 137) | -2.7% (-10.2 to 5.4) | 8371 | 181 (-303 to 639.3) | 2.2% (-3.5 to 8.3) | |||
| Oral or inactivated polio (3) | 3096 | 370 (134.5 to 544.5) | 13.6% (4.5 to 21.3) | 2993 | -296.5 (-532.1 to -94.4) | -9% (-15.1 to -3.1) | 2655 | -439.5 (-728.1 to -228.4) | -14.2% (-21.5 to -7.9) | 8744 | -364.5 (-980.8 to 99.5) | -4% (-10.1 to 1.2) | |||
| Pentavalent (1) | 2976 | 269 (69.9 to 434) | 9.9% (2.4 to 17.1) | 2861 | -409.5 (-627.6 to -214) | -12.5% (-18 to -7) | 2692 | -301 (-547.1 to -99.1) | -10.1% (-16.9 to -3.6) | 8529 | -453 (-964.2 to -36) | -5% (-10.2 to -0.4) | |||
| Pentavalent (2) | 2904 | 399 (234.9 to 567.5) | 15.9% (8.8 to 24.3) | 2683 | -248 (-474.6 to -42) | -8.5% (-15 to -1.5) | 2494 | -247.5 (-472.5 to -23) | -9% (-15.9 to -0.9) | 8081 | -103.5 (-525.1 to 346.6) | -1.3% (-6.1 to 4.5) | |||
| Pentavalent (3) | 3119 | 398.5 (179.8 to 573) | 14.6% (6.1 to 22.5) | 3001 | -236 (-470 to -22.9) | -7.3% (-13.5 to -0.8) | 2793 | -261 (-512.1 to -23.5) | -8.5% (-15.5 to -0.8) | 8913 | -105 (-714.3 to 397.6) | -1.2% (-7.4 to 4.7) | |||
| Pneumococcal conjugate (1) | 2952 | 278 (83.5 to 442.1) | 10.4% (2.9 to 17.6) | 2830 | -409 (-631.6 to -219.8) | -12.6% (-18.2 to -7.2) | 2788 | -168.5 (-420.4 to 51) | -5.7% (-13.1 to 1.9) | 8570 | -302.5 (-845.1 to 184.8) | -3.4% (-9 to 2.2) | |||
| Pneumococcal conjugate (2) | 2889 | 384 (197.5 to 558) | 15.3% (7.3 to 23.9) | 2749 | -184 (-436.7 to 3.7) | -6.3% (-13.7 to 0.1) | 2641 | -115.5 (-362.1 to 87.6) | -4.2% (-12.1 to 3.4) | 8279 | 81.5 (-454.1 to 540.1) | 1% (-5.2 to 7) | |||
| Pneumococcal conjugate (3) | 3096 | 374 (183.9 to 535) | 13.7% (6.3 to 20.9) | 2978 | -287 (-486.6 to -95.3) | -8.8% (-14 to -3.1) | 2792 | -257 (-481.1 to -59.4) | -8.4% (-14.7 to -2.1) | 8866 | -173.5 (-635.5 to 278.5) | -1.9% (-6.7 to 3.2) | |||
| Rotavirus (1) | 2946 | 234 (43 to 386) | 8.6% (1.5 to 15.1) | 2934 | -507.5 (-738.1 to -308) | -14.7% (-20.1 to -9.5) | 2840 | -234 (-463.5 to -27.4) | -7.6% (-14 to -1) | 8720 | -520 (-992.6 to -48.9) | -5.6% (-10.2 to -0.6) | |||
| Rotavirus (2) | 3039 | 465.5 (296.4 to 623) | 18.1% (10.8 to 25.8) | 2778 | -302 (-530 to -124) | -9.8% (-16 to -4.3) | 2570 | -317.5 (-576.1 to -110.5) | -11% (-18.3 to -4.1) | 8387 | -174 (-656.6 to 292) | -2% (-7.3 to 3.6) | |||
| Measles (1) | 2868 | 722 (168.5 to 1019) | 33.6% (6.2 to 55.1) | 2888 | -118 (-700.6 to 321) | -3.9% (-19.5 to 12.5) | 2517 | 366 (-176.1 to 658) | 17% (-6.5 to 35.4) | 8273 | 926 (-232.9 to 1710.6) | 12.6% (-2.7 to 26.1) | |||
NA: data not available; PI: prediction interval.
Note: Cumulative differences across three periods will only approximately sum to cumulative difference for entire period as we report the median value across bootstrap samples.